What Us2.ai does

Us2.ai (legally Eko.ai Pte. Ltd.) is a Singapore-headquartered healthtech company that develops FDA-cleared and CE-marked artificial intelligence software for fully automated echocardiography analysis. The platform processes DICOM ultrasound images from any major vendor — GE HealthCare, Philips, Siemens, Canon, Fujifilm, and handheld POCUS devices — and delivers a structured clinician-ready report, including automated measurements (LVEF, GLS, diastolic function), disease detection (heart failure subtypes, cardiac amyloidosis, aortic stenosis, pulmonary hypertension), and stress echocardiography analysis, in seconds with no manual frame selection or annotations. The system is differentiated by being the first and only platform to combine deep learning pattern recognition with guideline-based echocardiographic measurements for automated cardiac amyloidosis detection, and is supported by 150+ peer-reviewed publications in journals including Nature Communications, The Lancet Digital Health, European Heart Journal, JACC, and Circulation.

The platform is offered as cloud-managed SaaS or on-premise (air-gap compatible) deployment, connecting to existing PACS, CVIS, and EMR systems via standard DICOM routing, with a typical go-live timeline of approximately one month. Us2.ai serves cardiologists, sonographers, core labs, and hospitals/health systems, and is increasingly being deployed in primary-care and community screening settings (PANACEA-HF in Australia, Everton BEAT Breathlessness with the NHS in the UK). The company operates across 28+ regulated markets, has 500+ hospital deployments, and reports 1M+ echocardiography scans analyzed on the platform. Regulatory clearances include FDA 510(k), CE Mark (Class IIb under EU MDR), MHRA, TGA, Health Canada, PMDA, HSA, plus ISO 27001:2022, SOC 2 Type II, MDSAP, HIPAA, and GDPR certifications.

The business model is annual subscription SaaS (cloud or on-premise), priced via quote-based enterprise contracts that vary by deployment type, institution size, and scan volume. Distribution combines direct enterprise field sales with channel leverage through partnerships with GE HealthCare, Fujifilm, Canon Medical Systems, Microsoft, Viz.ai, Aidoc, and academic medical centers including Duke University and Brigham and Women's Hospital. The company is venture-backed, having closed a US$15 million Series A in April 2022 co-led by IHH Healthcare and Heal Partners with participation from Sequoia India, and is led by co-founder and CEO James Hare.

Name

Us2.ai

Legal name

Eko.ai Pte. Ltd.

Website

https://us2.ai

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Us2.ai (legally Eko.ai Pte. Ltd.) is a Singapore-based healthtech company that builds FDA-cleared, CE-marked AI software for fully automated echocardiography analysis, serving hospitals, echo labs, cardiologists, sonographers, and core labs across 28+ countries.

Ownership category

akta.pro rank

Product category

AI Echocardiography Software

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Medical Imaging AI (HDAAAEAH), Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE)

Keywords

• AI echocardiography software
• Automated echo reporting
• Cardiac ultrasound analysis
• Heart failure detection AI
• Cardiac amyloidosis screening

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Software Subscription (SaaS): Us2.ai generates revenue through software subscriptions for its FDA-cleared AI echocardiography platform. The platform is offered as a cloud-hosted SaaS solution or on-premise deployment. Revenue is driven by hospital and echo lab deployments, with typical go-live timelines of approximately one month. The company is expanding globally across the US, Europe, and Asia following its Series A funding.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Us2.ai develops FDA-cleared, CE-marked AI software that fully automates echocardiography analysis. Its deep learning platform processes DICOM ultrasound images from any vendor to deliver a complete structured report—including measurements, disease detection, and findings—in seconds with zero clicks required. The platform addresses echo lab throughput bottlenecks by replacing manual measurement workflows with automated analysis covering cardiac amyloidosis, heart failure, aortic stenosis, pulmonary hypertension, and strain imaging.

Product overview

Us2.ai is a unified AI platform for fully automated echocardiography analysis. The core Us2.ai AI Platform delivers end-to-end echo reporting from DICOM upload to structured report in seconds, encompassing automated measurements, disease detection, and guideline-based findings. The platform integrates specialized detection modules for Cardiac Amyloidosis (FDA cleared/CE marked, combining deep learning pattern recognition with echocardiographic measurements), Heart Failure (automated LVEF, GLS, diastolic function, and HFpEF detection), Aortic Stenosis, Pulmonary Hypertension, Strain imaging, and Stress Echocardiography. Deployment is available as Cloud (managed hosting) or On-premise (dedicated hardware with air-gap compatibility), connecting to existing ultrasound devices, PACS, CVIS, and EMR systems via standard DICOM routing.

Differentiator

Problem solved

Functional benefit

Products and services

• Us2.ai AI Platform FDA-cleared, CE-marked AI software that fully automates echocardiography analysis, delivering measurements, disease detection, and structured reports from DICOM uploads in seconds. Designed for hospital echo labs, health systems, core labs, cardiologists, and sonographers facing reporting throughput bottlenecks.

Quantifiable outcome

• 70% reduction in echocardiography reporting time (35-40 min/study reduced to approximately 10 min/study)
• +7 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered core and strategic.

• University of Notre Dame AustraliacoreStrategic or Co-development Partner · 27 June 2025Professor Simon Stewart from the University of Notre Dame Australia leads the PANACEA-HF study, a $2 million MRFF-funded initiative deploying Us2.ai's AI-PoCUS technology for heart failure screening in Australian primary care. The partnership demonstrates academic collaboration for clinical research and population health screening.
• GE HealthCarecoreTechnology or IntegrationGE HealthCare is a technology and integration partner of Us2.ai. The companies work together to enable Us2.ai's AI echocardiography analysis on GE HealthCare ultrasound devices. GE HealthCare is listed as a partner on Us2.ai's website.
• FujifilmcoreTechnology or IntegrationFujifilm is a technology and integration partner of Us2.ai, enabling Us2.ai's AI echocardiography analysis on Fujifilm ultrasound systems. Fujifilm is listed as a partner on Us2.ai's website.
• Canon Medical SystemscoreTechnology or IntegrationCanon Medical Systems is a technology and integration partner of Us2.ai, enabling Us2.ai's AI echocardiography analysis on Canon Medical ultrasound systems. Canon Medical is listed as a partner on Us2.ai's website.
• MicrosoftstrategicTechnology or IntegrationMicrosoft is listed as a technology partner of Us2.ai. The partnership involves cloud infrastructure and platform services supporting Us2.ai's AI echocardiography deployment capabilities.
• Viz.aistrategicTechnology or IntegrationViz.ai is a cardiovascular AI partner of Us2.ai. Chris Mansi, CEO of Viz.ai, stated: 'We are proud to partner with Us2.ai to enhance and complement our comprehensive AI platform, tailoring it to cardiovascular needs.' The partnership integrates Us2.ai's echo analysis with Viz.ai's broader cardiovascular AI platform.
• AidocstrategicTechnology or IntegrationAidoc is a healthcare AI partner of Us2.ai. Elad Walach, CEO of Aidoc, stated: 'Our partnership with Us2.ai allows our health system partners to further expand the clinical value of AI to cardiac care.' The partnership integrates Us2.ai into Aidoc's aiOS platform for health system-wide AI deployment.
• Duke UniversitystrategicStrategic or Co-development PartnerDuke University is an academic medical center partner of Us2.ai. Dr. Sreekanth Vemulapalli, Associate Professor of Medicine at Duke University, is quoted endorsing Us2.ai's platform and noting its potential for enabling echocardiography in screening at accelerated pace and cost-effective manner.
• Brigham and Women's HospitalstrategicStrategic or Co-development PartnerBrigham and Women's Hospital is listed as an academic medical center partner of Us2.ai. The partnership involves clinical collaboration, research, and validation of Us2.ai's AI echocardiography platform.
• NHS Liverpool University Hospitals / Everton in the CommunitystrategicStrategic or Co-development PartnerThe Everton BEAT Breathlessness project is a BHF-funded community diagnostic initiative in North Liverpool, UK. It is a partnership between NHS providers, Everton in the Community, the Pumping Marvellous Foundation, public health organizations, and Liverpool City Council. Us2.ai's AI echocardiography is deployed in community settings operated by heart failure specialist nurses under cardiologist oversight, targeting 1,500 patients over 12 months.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Caption Health: AI echocardiography software company acquired by GE HealthCare in 2023. Caption Health's AI guidance and automated ejection fraction / strain measurement is the closest direct peer to Us2.ai, addressing similar clinical workflows and use cases. Now resourced by GE as part of its broader ultrasound AI strategy.
• Ultromics: UK-based AI echocardiography company with the EchoGo platform focused on automated heart failure detection (including HFpEF). Direct peer with FDA-cleared AI for HFpEF using similar deep learning approaches to Us2.ai's heart failure module, and a competitor for the same clinical and core lab use cases.
• EchoNous: AI-enabled handheld and point-of-care ultrasound company (Kosmos platform) combining AI-guided image acquisition with cardiac analysis. Direct competitor in AI-driven cardiac imaging at the point of care, particularly relevant to Us2.ai's expansion into primary care and community screening settings.

Broad incumbents

• GE HealthCare: Global ultrasound OEM that acquired Caption Health in 2023 and embeds native AI echo capabilities across Vscan, Vivid, and Venue systems. Major listed Us2.ai distribution partner but also a competitor via bundled AI, with the installed base and sales force to favor proprietary AI in newer fleets.
• Philips: Major ultrasound OEM with Philips Cardiac Workspace and AI echo capabilities built into EPIQ CVx and Affiniti systems. Notable as not listed among Us2.ai's current OEM partners despite significant global echo market share, representing both a partnership opportunity and a competitive threat.
• Siemens Healthineers: Ultrasound OEM with AI-augmented echocardiography features on ACUSON systems including automated measurements and strain. Competes with Us2.ai through native AI capabilities while also being a potential integration partner for the vendor-neutral platform.

Emerging players

• Circle Cardiovascular Imaging: Cardiac imaging AI platform for MRI, CT, and echo post-processing with strong presence in clinical research and core lab operations. Comparable to Us2.ai's core lab solutions and standardized measurement capabilities, often co-deployed in multi-modality research workflows.
• HeartFlow: Cardiac imaging AI company specializing in CT-based FFR analysis for coronary disease. While focused on CT rather than echo, HeartFlow is a comparable AI-driven cardiac diagnostic company targeting similar clinical decision support use cases and similar hospital economics (CPT reimbursement, FDA clearance, clinical adoption).

Others

• Aidoc: Healthcare AI platform company with the aiOS operating system for hospital-wide AI deployment. Strategic integration partner of Us2.ai (cardiology module on aiOS), but also an adjacent AI healthcare company whose platform-level approach could complement or compete with vendor-specific AI solutions depending on hospital purchasing structure.
• Viz.ai: Cardiovascular AI platform company focused on stroke and cardiology care coordination. Strategic partner that integrates Us2.ai's echo analysis within its broader cardiovascular AI platform, demonstrating ecosystem alignment rather than direct competition — relevant for understanding the AI cardiology stack Us2.ai sits within.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/us2_ai
• LinkedInlinkedin.com/company/us2-ai

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Us2.ai